Cargando…

Brolucizumab—another anti-VEGF or beyond

Detalles Bibliográficos
Autores principales:	Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D., Loewenstein, Anat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608128/ https://www.ncbi.nlm.nih.gov/pubmed/32317791 http://dx.doi.org/10.1038/s41433-020-0888-y

Ejemplares similares

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Smartphone based ROP (S-ROP) screening—opportunities and challenges
por: patil, Jayaprakash, et al.
Publicado: (2020)

Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum
por: Sheth, Jay, et al.
Publicado: (2020)

Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India
por: Sharma, Ashish, et al.
Publicado: (2022)

Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
por: Sharma, Ashish, et al.
Publicado: (2023)

Ranizurel safety evaluation in real-world -(RaSER) study
por: Sharma, Ashish, et al.
Publicado: (2022)

Commentary: Acute central serous chorioretinopathy – Treat early, observe longer
por: Kumar, Nilesh, et al.
Publicado: (2021)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

Correction: Comment on: ‘Recent advances in anterior chamber angle imaging’
por: Kumar, Nilesh, et al.
Publicado: (2020)

Comment on: ‘Recent advances in anterior chamber angle imaging’
por: Kumar, Nilesh, et al.
Publicado: (2020)

Biosimilars in ophthalmology: “Is there a big change on the horizon?”
por: Sharma, Ashish, et al.
Publicado: (2018)

Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy
por: Murray, Julianna E, et al.
Publicado: (2021)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases
por: Lanzetta, Paolo, et al.
Publicado: (2017)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

Another piece in the COVID-19 treatment puzzle
por: Mussini, Cristina, et al.
Publicado: (2022)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Equity in excellence or just another tax on Black skin?
por: Obasi, Angela I
Publicado: (2020)

NKG2A and COVID-19: another brick in the wall
por: Antonioli, Luca, et al.
Publicado: (2020)

COVID-19 vaccines for children in LMICs: another equity issue
por: Kampmann, Beate, et al.
Publicado: (2021)

COVID-19 and inhaled corticosteroids—another piece in an expanding puzzle
por: Schultze, Anna, et al.
Publicado: (2021)

Functional lung morphometry: another piece in the BPD prediction puzzle?
por: Poh, Qi Hui, et al.
Publicado: (2023)

Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel, Pravin U, et al.
Publicado: (2015)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Use of Intravitreal Triamcinolone in the Treatment of Macular Edema Related to Retinal Vein Occlusion
por: Sharma, Ashish, et al.
Publicado: (2008)

Alive another day
por: BOGDANOVIC, Nenad
Publicado: (2007)

Another Unanswerable Question
por: Jaffe, Allan S.
Publicado: (2017)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Rigorous and consistent evaluation of diagnostic tests in children: another unmet need
por: Caldwell, Christine S., et al.
Publicado: (2020)

Yet another reason we need to tackle socioeconomic inequalities in smoking
por: Green, Michael J.
Publicado: (2022)

Brolucizumab for macular degeneration
Publicado: (2020)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
por: Lally, David R., et al.
Publicado: (2022)

Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy
por: Borrelli, Enrico, et al.
Publicado: (2020)

Open data could have helped us learn from another mining dam disaster
por: de Souza, Paulo A.
Publicado: (2019)

From choice architecture to choice engineering
por: Dan, Ohad, et al.
Publicado: (2019)

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
por: Lally, David R., et al.
Publicado: (2022)

Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment
por: Golan, Shani, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b0cl5ulg87491gpsf4lc8fkr8c